Rankings / Weight Loss — Incretins & Amylin
Semaglutide
Weight loss · GLP-1 agonist
Tier B+
What this is
STEP 1: ~15% body weight loss over 68 weeks. SELECT 2023: 20% reduction in MACE in obese patients with CVD but no diabetes. GI side effects common; rare pancreatitis/gallbladder. Weight regain on cessation.
Mechanism
GLP-1 receptor agonist: slows gastric emptying; suppresses glucagon; enhances glucose-dependent insulin secretion; central appetite suppression via hypothalamic GLP-1R
Dose & route
Wegovy (obesity): titrate to 2.4 mg SC weekly; Ozempic (T2DM): 0.25-2 mg SC weekly
Citations
- https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.